Siddharth Kumar Das
Research Subjects
Siddharth Kumar Das has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Ragini Srivastava
Department of Rheumatology King Georg's Medical University Lucknow UP India
4 shared publications- Ali Mobasheri
Department of Personalized Medicine, State Research Center for Innovative Medicine, Vilnius, Lithuania
3 shared publications - Changhai Ding
Clinical Research Centre, Zhujiang Hospital Southern Medical University Guangzhou Guangdong China
3 shared publications Girdhar G. Agarwal
Department of Statistics Lucknow University Lucknow UP India
3 shared publications- Ida Kristin Haugen
Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway
3 shared publications - Margreet Kloppenburg
Department of Rheumatology Leiden University Medical Center Leiden The Netherlands
3 shared publications
Latest Publications
- Open Access
- 23 May 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (9) , 1141-1146
OARSI initiative to develop classification criteria for early-stage symptomatic knee OA (EsSKOA): What conditions should be considered in the differential diagnosis of EsSKOA?
- 23 May 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (9) , 1141-1146
Open AccessOARSI initiative to develop classification criteria for early-stage symptomatic knee OA (EsSKOA): What conditions should be considered in the differential diagnosis of EsSKOA?
- 3 February 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (2) , e70106
Efficacy and Safety of Tocilizumab in Polymyalgia Rheumatica: A Systematic Review and Meta‐Analysis
Aims: No meta‐analysis has holistically analyzed and summarized the efficacy and safety of tocilizumab in polymyalgia rheumatica (PMR). We undertook this meta‐analysis to address this knowledge‐gap.Methods: Electronic databases were searched for RCTs involving patients living with PMR receiving tocilizumab in intervention arm, and placebo/active comparator in control arm. Primary outcome was to evaluate percentage of patients able to achieve C‐reactive protein PMR assessment score (CRP‐PMR‐AS) < 10 or prednisolone dose < 5 mg/day or > 10 mg/dL decline in prednisolone from baseline. Secondary outcomes were to determine percentage of patients able to totally stop prednisolone and adverse‐events.Results: From initially screened 115 articles, data from 2 RCTs (136 patients) was analyzed. In addition, a descriptive analysis of 8 observational studies (356 patients) was also done. After 24‐weeks of clinical use, patients with PMR receiving tocilizumab had significantly higher chances of achieving composite primary end‐point defined as CRP‐PMR‐AS < 10 and either prednisone dosage < 5 mg/day or decrease in prednisolone dosage by > 10 mg/day compared to baseline [odds ratio (OR) 4.89 (95% CI: 2.34–10.23); p < 0.001; I2 = 0%], compared to placebo. Patients with PMR receiving tocilizumab also had significantly higher chances of being able to stop prednisolone compared to placebo [OR 4.45 (95% CI: 2.06–9.61); p < 0.001; I2 = 0%]. Occurrence of total adverse‐events [risk ratio (RR) 1.24 (95% CI: 0.50–3.12); p = 0.64; I2 = 0%], adverse‐events leading to treatment discontinuation [RR 0.45 (95% CI: 0.10–2.02); p = 0.29; I2 = 17%], and infections [RR 1.71 (95% CI: 0.83–3.52); p = 0.14; I2 = 6%] were comparable in patients receiving tocilizumab as compared to placebo. Observational studies have noted lung infections, neutropenia and increased cholesterol with tocilizumab use.Conclusion: Tocilizumab is well tolerated and is effective for managing PMR. Tocilizumab is an effective glucocorticoid sparing agent in PMR.
- 3 February 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (2) , e70106
Efficacy and Safety of Tocilizumab in Polymyalgia Rheumatica: A Systematic Review and Meta‐Analysis
Aims: No meta‐analysis has holistically analyzed and summarized the efficacy and safety of tocilizumab in polymyalgia rheumatica (PMR). We undertook this meta‐analysis to address this knowledge‐gap.Methods: Electronic databases were searched for RCTs involving patients living with PMR receiving tocilizumab in intervention arm, and placebo/active comparator in control arm. Primary outcome was to evaluate percentage of patients able to achieve C‐reactive protein PMR assessment score (CRP‐PMR‐AS) < 10 or prednisolone dose < 5 mg/day or > 10 mg/dL decline in prednisolone from baseline. Secondary outcomes were to determine percentage of patients able to totally stop prednisolone and adverse‐events.Results: From initially screened 115 articles, data from 2 RCTs (136 patients) was analyzed. In addition, a descriptive analysis of 8 observational studies (356 patients) was also done. After 24‐weeks of clinical use, patients with PMR receiving tocilizumab had significantly higher chances of achieving composite primary end‐point defined as CRP‐PMR‐AS < 10 and either prednisone dosage < 5 mg/day or decrease in prednisolone dosage by > 10 mg/day compared to baseline [odds ratio (OR) 4.89 (95% CI: 2.34–10.23); p < 0.001; I2 = 0%], compared to placebo. Patients with PMR receiving tocilizumab also had significantly higher chances of being able to stop prednisolone compared to placebo [OR 4.45 (95% CI: 2.06–9.61); p < 0.001; I2 = 0%]. Occurrence of total adverse‐events [risk ratio (RR) 1.24 (95% CI: 0.50–3.12); p = 0.64; I2 = 0%], adverse‐events leading to treatment discontinuation [RR 0.45 (95% CI: 0.10–2.02); p = 0.29; I2 = 17%], and infections [RR 1.71 (95% CI: 0.83–3.52); p = 0.14; I2 = 6%] were comparable in patients receiving tocilizumab as compared to placebo. Observational studies have noted lung infections, neutropenia and increased cholesterol with tocilizumab use.Conclusion: Tocilizumab is well tolerated and is effective for managing PMR. Tocilizumab is an effective glucocorticoid sparing agent in PMR.
- Open Access
- 31 January 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (4) , 530-533
Corrigendum to “Multi-centre modified Delphi exercise to identify candidate items for classifying early-stage symptomatic knee osteoarthritis” [Osteoarthritis Cartilage (2025) 155–165]
- 31 January 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (4) , 530-533
Open AccessCorrigendum to “Multi-centre modified Delphi exercise to identify candidate items for classifying early-stage symptomatic knee osteoarthritis” [Osteoarthritis Cartilage (2025) 155–165]
- 1 April 2021
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 29, S2-S4
2020-2021 Board of Directors
- 1 April 2021
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 29, S2-S4
2020-2021 Board of Directors
- Open Access
- 4 September 2018
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 21 (11) , 1894-1899
Distribution of rheumatological diseases in rural and urban areas: An adapted COPCORD Stage I Phase III survey of Lucknow district in north India
Objectives: To study the distribution of various rheumatological diseases in rural and urban areas of Lucknow, India.Method: A study using adapted a Community Oriented Program for the Control of Rheumatic Diseases scheme was carried out in a cluster of rural (n = 5118) and urban (n = 5053) communities through a door‐to‐door survey. Trained community volunteers completed the questionnaires. Patients with musculoskeletal pain (MSK pain) were clinically evaluated by a physician. X‐ray examinations and blood investigations were also done. Diagnosis was made according to International Classification of Diseases‐9 classification system.Results: Among persons reporting MSK pain in rural areas, high prevalence of osteoarthritis (OA) knee (35%) was observed followed by fibromyalgia (32.1%), backache (28.4%), non‐specific pain (NSP) (20.7%) and rheumatoid arthritis (RA) (1.2%). In urban area, OA knee (36.3%) and backache (36.6%) were found highly prevalent, followed by fibromyalgia (11.1%), NSP (10.9%) and neck pain (7.4%). In urban areas among MSK pain patients, prevalence of RA was only 1.6%. Age‐adjusted analysis among urban people showed backache complaints begin early (>20 years) than rural people. Significantly higher numbers of Knee OA complaints emerged among urban people than rural in the age group 21‐60 years. Projected population prevalence of knee OA was 44.9 and 106.07/1000 in rural and urban areas, respectively. Further projected population prevalences of fibromyalgia, backache, RA and NSP in rural and urban areas are 41.2 and 32.4, 36.5 and 106.6, 1.56 and 4.74, 26.0 and 32.0 per 1000, respectively.Conclusion: OA knee, fibromyalgia, backache and NSP are predominant health problems of both areas. Female preponderance was observed in all rheumatological diseases in both the areas.
- 4 September 2018
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 21 (11) , 1894-1899
Open AccessDistribution of rheumatological diseases in rural and urban areas: An adapted COPCORD Stage I Phase III survey of Lucknow district in north India
Objectives: To study the distribution of various rheumatological diseases in rural and urban areas of Lucknow, India.Method: A study using adapted a Community Oriented Program for the Control of Rheumatic Diseases scheme was carried out in a cluster of rural (n = 5118) and urban (n = 5053) communities through a door‐to‐door survey. Trained community volunteers completed the questionnaires. Patients with musculoskeletal pain (MSK pain) were clinically evaluated by a physician. X‐ray examinations and blood investigations were also done. Diagnosis was made according to International Classification of Diseases‐9 classification system.Results: Among persons reporting MSK pain in rural areas, high prevalence of osteoarthritis (OA) knee (35%) was observed followed by fibromyalgia (32.1%), backache (28.4%), non‐specific pain (NSP) (20.7%) and rheumatoid arthritis (RA) (1.2%). In urban area, OA knee (36.3%) and backache (36.6%) were found highly prevalent, followed by fibromyalgia (11.1%), NSP (10.9%) and neck pain (7.4%). In urban areas among MSK pain patients, prevalence of RA was only 1.6%. Age‐adjusted analysis among urban people showed backache complaints begin early (>20 years) than rural people. Significantly higher numbers of Knee OA complaints emerged among urban people than rural in the age group 21‐60 years. Projected population prevalence of knee OA was 44.9 and 106.07/1000 in rural and urban areas, respectively. Further projected population prevalences of fibromyalgia, backache, RA and NSP in rural and urban areas are 41.2 and 32.4, 36.5 and 106.6, 1.56 and 4.74, 26.0 and 32.0 per 1000, respectively.Conclusion: OA knee, fibromyalgia, backache and NSP are predominant health problems of both areas. Female preponderance was observed in all rheumatological diseases in both the areas.
- 27 October 2017
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 20 (11) , 1638-1647
Prevalence of rheumatic musculoskeletal symptoms in rural and urban areas : a cross‐sectional study in northern India
Objectives: To study the prevalence of rheumatic musculoskeletal symptoms in rural and urban areas of Lucknow.Method: The survey was carried out in a cluster of rural (n = 5118) and urban (n = 5053) communities of Lucknow through a door‐to‐door survey. Demographic data were collected and subjects with musculoskeletal pain (MSK pain) were identified. A Hindi adapted version of the Community Oriented Program for the Control of Rheumatic Diseases questionnaire was used. Trained community volunteers completed the questionnaire.Results: Present and past MSK pain was the most common self‐reported problem in urban areas (34.1%), while it was the third most common self‐reported problem in rural areas (15.1%), after abdominal pain and cough. Females (214.9 and 419.5 per 1000) were more affected than males (118.8 and 265.2 per 1000) in rural and urban areas, respectively. Point prevalence of MSK pain (pain in last week) was higher in urban areas (28.2%) compared to rural areas (14.1%). In rural as well as urban areas, knee (rural: 49.3%, urban: 50.6%) and spine (rural: 56%, urban: 43.6%) were highly reported pain sites. Fatigue ([n] rural: 328, urban: 368) weakness ([n] rural: 310, urban: 324) and anorexia ([n] rural: 84, urban: 142) were most common systemic symptoms reported by urban as well as rural people. Urethritis/balanitis and ulcers in the mouth were the most common other symptoms reported by people in both the areas.Conclusion: MSK pain is a predominant health problem of both rural and urban areas. Sex‐adjusted prevalence is higher among females than males. Knee and back were highly prevalent pain sites in both rural and urban areas of Lucknow.
- 27 October 2017
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 20 (11) , 1638-1647
Prevalence of rheumatic musculoskeletal symptoms in rural and urban areas : a cross‐sectional study in northern India
Objectives: To study the prevalence of rheumatic musculoskeletal symptoms in rural and urban areas of Lucknow.Method: The survey was carried out in a cluster of rural (n = 5118) and urban (n = 5053) communities of Lucknow through a door‐to‐door survey. Demographic data were collected and subjects with musculoskeletal pain (MSK pain) were identified. A Hindi adapted version of the Community Oriented Program for the Control of Rheumatic Diseases questionnaire was used. Trained community volunteers completed the questionnaire.Results: Present and past MSK pain was the most common self‐reported problem in urban areas (34.1%), while it was the third most common self‐reported problem in rural areas (15.1%), after abdominal pain and cough. Females (214.9 and 419.5 per 1000) were more affected than males (118.8 and 265.2 per 1000) in rural and urban areas, respectively. Point prevalence of MSK pain (pain in last week) was higher in urban areas (28.2%) compared to rural areas (14.1%). In rural as well as urban areas, knee (rural: 49.3%, urban: 50.6%) and spine (rural: 56%, urban: 43.6%) were highly reported pain sites. Fatigue ([n] rural: 328, urban: 368) weakness ([n] rural: 310, urban: 324) and anorexia ([n] rural: 84, urban: 142) were most common systemic symptoms reported by urban as well as rural people. Urethritis/balanitis and ulcers in the mouth were the most common other symptoms reported by people in both the areas.Conclusion: MSK pain is a predominant health problem of both rural and urban areas. Sex‐adjusted prevalence is higher among females than males. Knee and back were highly prevalent pain sites in both rural and urban areas of Lucknow.
- 28 March 2016
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 19 (3) , 215-218
Current biological understanding and futuristic views for osteoarthritis treatment: Optimistic or otherwise?
- 28 March 2016
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 19 (3) , 215-218
Current biological understanding and futuristic views for osteoarthritis treatment: Optimistic or otherwise?
- Open Access
- 1 November 2014
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 9, S64
Practical utility of cognitive behaviour therapy in patients of fibromyalgia
- 1 November 2014
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 9, S64
Open AccessPractical utility of cognitive behaviour therapy in patients of fibromyalgia
- Open Access
- 1 January 2014
- Published by Wiley in Interdisciplinary Perspectives on Infectious Diseases
- Vol. 2014, 1-5
Steroids Decrease Prevalence of Positive Tuberculin Skin Test in Rheumatoid Arthritis: Implications on Anti-TNF Therapies
Tuberculin skin test has been used as an indicator of latent tuberculosis in patients with Rheumatoid Arthritis (RA) before administration of biologicals. Effect of Disease modifying antirheumatic drugs (DMARDs) and steroids on the result of tuberculin skin test (TST) may have important implications in interpretation of results of this test.Objectives. To find the prevalence of positive TST in rheumatoid patients and the effect of standard treatment on the results of TST.Method. In this cross-sectional study two hundred and fifty patients of RA above 18 years of age, classified using 1987 ACR criteria for RA, were enrolled from rheumatology outdoor. Demographics, disease activity, disease duration, and therapy were recorded. All patients underwent TST.Results. Fifty-one (20.4%) patients were found to be tuberculin positive. Tuberculin positivity was not affected by MTX intake but it was significantly low in patients with recent steroid intake as compared to patients who had not taken steroids in last 3 months (3% versus 25%,P= 0.002).Conclusion. Prevalence of tuberculin positivity in patients with RA was found to be low. Results were not affected by methotrexate; however tuberculin skin test results in patients with recent use of steroids are likely to be negative.
- 1 January 2014
- Published by Wiley in Interdisciplinary Perspectives on Infectious Diseases
- Vol. 2014, 1-5
Open AccessSteroids Decrease Prevalence of Positive Tuberculin Skin Test in Rheumatoid Arthritis: Implications on Anti-TNF Therapies
Tuberculin skin test has been used as an indicator of latent tuberculosis in patients with Rheumatoid Arthritis (RA) before administration of biologicals. Effect of Disease modifying antirheumatic drugs (DMARDs) and steroids on the result of tuberculin skin test (TST) may have important implications in interpretation of results of this test.Objectives. To find the prevalence of positive TST in rheumatoid patients and the effect of standard treatment on the results of TST.Method. In this cross-sectional study two hundred and fifty patients of RA above 18 years of age, classified using 1987 ACR criteria for RA, were enrolled from rheumatology outdoor. Demographics, disease activity, disease duration, and therapy were recorded. All patients underwent TST.Results. Fifty-one (20.4%) patients were found to be tuberculin positive. Tuberculin positivity was not affected by MTX intake but it was significantly low in patients with recent steroid intake as compared to patients who had not taken steroids in last 3 months (3% versus 25%,P= 0.002).Conclusion. Prevalence of tuberculin positivity in patients with RA was found to be low. Results were not affected by methotrexate; however tuberculin skin test results in patients with recent use of steroids are likely to be negative.
- 1 October 2013
- Published by Springer Nature in Sleep and Biological Rhythms
- Vol. 11 (4) , 261-267
Circadian variations of 5-hydroxytryptamine in female with fibromyalgia syndrome: A case control study
- 1 October 2013
- Published by Springer Nature in Sleep and Biological Rhythms
- Vol. 11 (4) , 261-267
Circadian variations of 5-hydroxytryptamine in female with fibromyalgia syndrome: A case control study